在过去的十年里,肺超声（LUS）B线和血清KrebsvondenLungen-6（KL-6）抗原已被认为是结缔组织疾病相关间质性肺病（CTD-ILD）的生物标志物。可靠的数据表明，B线总数和KL-6水平与高分辨率计算机断层扫描结果相关，肺功能测试,CTD-ILD的一些临床参数。然而,关于使用这两种生物标志物来追踪CTD-ILD的数据有限.在这里，我们报道一例抗黑素瘤分化相关基因5抗体阳性的临床肌病性皮肌炎相关ILD，成功用大剂量甲基强的松龙治疗，环磷酰胺,静脉注射免疫球蛋白，吡非尼酮,随后使用肺部超声和KL-6。
In the past decade, lung ultrasound (LUS) B-lines and serum Krebs von den Lungen-6 (KL-6) antigen have been recognized as biomarkers of the connective tissue disease-associated interstitial lung diseases (CTD-ILDs). Robust data have demonstrated that B-lines total numbers and KL-6 levels are correlated with high-resolution computed tomography findings, pulmonary function test, and some clinical parameters in CTD-ILDs. However, limited data are available regarding the use of these two biomarkers to follow CTD-ILDs. Herein, we report a
case with anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis-associated ILD, successfully treated with high-dose methylprednisolone, cyclophosphamide, intravenous immunoglobulin, pirfenidone, and followed using lung ultrasound and KL-6.
